688298.SS SHH
Zhejiang Orient Gene Biotech Co., Ltd
1W: +2.0%
1M: +0.9%
3M: +1.1%
YTD: -22.0%
1Y: -32.0%
3Y: -49.3%
5Y: -81.0%
¥19.37 ($2.89)
+0.45 (+2.38%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$8.1B
-10.0% ▼
5Y CAGR: +86.2%
Total Liabilities
$1.3B
-9.9% ▼
5Y CAGR: +64.7%
Shareholders Equity
$6.6B
-10.6% ▼
5Y CAGR: +92.4%
Cash & Investments
$3.3B
-37.0% ▼
5Y CAGR: +107.5%
Total Debt
$164M
-73.1% ▼
5Y CAGR: +43.4%
Net Debt
-$2.9B
+18.0% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.0B | $6.1B | $6.6B | $4.2B | $3.1B |
| Short-Term Investments | $199M | $168M | $1.2B | $1.1B | $208M |
| Cash & ST Investments | $2.2B | $6.3B | $7.8B | $5.2B | $3.3B |
| Net Receivables | $670M | $1.2B | $382M | $228M | $249M |
| Inventory | $382M | $471M | $432M | $347M | $309M |
| Other Current Assets | $74M | $174M | $249M | $75M | $103M |
| Total Current Assets | $3.3B | $8.1B | $8.7B | $5.9B | $4.0B |
| Property, Plant & Equip. | $162M | $481M | $1.1B | $2.3B | $2.7B |
| Goodwill & Intangibles | $14M | $127M | $458M | $479M | $691M |
| Long-Term Investments | $5M | -$143M | -$1.1B | $52M | -$157M |
| Other Non-Current Assets | $27M | $315M | $1.4B | $61M | $573M |
| Total Non-Current Assets | $254M | $851M | $2.0B | $3.1B | $4.1B |
| Total Assets | $3.6B | $9.0B | $10.7B | $9.0B | $8.1B |
| — Liabilities — | |||||
| Accounts Payable | $372M | $1.2B | $1.6B | $578M | $515M |
| Short-Term Debt | $2M | $6M | $4M | $249M | $117M |
| Deferred Revenue | $326M | $877M | $339M | $0 | $0 |
| Other Current Liabilities | $413M | -$605M | $356M | $259M | $357M |
| Total Current Liabilities | $1.1B | $2.1B | $2.3B | $1.1B | $1.2B |
| Long-Term Debt | $3M | $0 | $50M | $300M | $0 |
| Other Non-Current Liab. | -$6M | $17M | $7M | $16M | $25M |
| Total Non-Current Liabilities | $9M | $30M | $102M | $360M | $99M |
| Total Liabilities | $1.1B | $2.1B | $2.4B | $1.4B | $1.3B |
| — Equity — | |||||
| Common Stock | $120M | $120M | $168M | $202M | $202M |
| Retained Earnings | $1.7B | $6.1B | $7.4B | $6.7B | $6.2B |
| Accumulated OCI | $56M | $51M | $113M | $0 | $143M |
| Total Stockholders Equity | $2.4B | $6.9B | $8.2B | $7.4B | $6.6B |
| Total Liabilities & Equity | $3.6B | $9.0B | $10.7B | $9.0B | $8.1B |
| — Key Metrics — | |||||
| Total Debt | $5M | $18M | $82M | $608M | $164M |
| Net Debt | -$2.0B | -$6.1B | -$6.5B | -$3.6B | -$2.9B |
| Total Investments | $199M | $25M | $36M | $1.1B | $50M |